3-Tyr-octreotide | CAS#103667-46-5

MedKoo Cat#: 462744 | Name: 3-Tyr-octreotide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

3-Tyr-octreotide is a biochemical that has been evaluated for tumor inhibition.

Chemical Structure

3-Tyr-octreotide

CAS#103667-46-5

Theoretical Analysis

MedKoo Cat#: 462744

Name: 3-Tyr-octreotide

CAS#: 103667-46-5

Chemical Formula: C49H66N10O11S2

Exact Mass: 1034.4354

Molecular Weight: 1035.25

Elemental Analysis: C, 56.85; H, 6.43; N, 13.53; O, 17.00; S, 6.19

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Sms-204-090; Sms 201-995, tyr(3)-;

IUPAC/Chemical Name

13-((1H-indol-3-yl)methyl)-19-(2-amino-3-phenylpropanamido)-10-(4-aminobutyl)-N-(1,3-dihydroxybutan-2-yl)-16-(4-hydroxybenzyl)-7-(1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide

InChi Key

LHCIROHUTQLZCZ-UHFFFAOYSA-N

InChi Code

InChI=1S/C49H66N10O11S2/c1-27(61)39(24-60)56-48(69)41-26-72-71-25-40(57-43(64)34(51)20-29-10-4-3-5-11-29)47(68)54-37(21-30-15-17-32(63)18-16-30)45(66)55-38(22-31-23-52-35-13-7-6-12-33(31)35)46(67)53-36(14-8-9-19-50)44(65)59-42(28(2)62)49(70)58-41/h3-7,10-13,15-18,23,27-28,34,36-42,52,60-63H,8-9,14,19-22,24-26,50-51H2,1-2H3,(H,53,67)(H,54,68)(H,55,66)(H,56,69)(H,57,64)(H,58,70)(H,59,65)

SMILES Code

CC(C(NC(C1CSSCC(C(NC(C(NC(C(NC(C(NC(C(N1)=O)C(O)C)=O)CCCCN)=O)Cc(c[nH]2)c3c2cccc3)=O)Cc4ccc(O)cc4)=O)NC(C(Cc5ccccc5)N)=O)=O)CO)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,035.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Banerjee I, De K, Mukherjee D, Dey G, Chattopadhyay S, Mukherjee M, Mandal M, Bandyopadhyay AK, Gupta A, Ganguly S, Misra M. Paclitaxel-loaded solid lipid nanoparticles modified with Tyr-3-octreotide for enhanced anti-angiogenic and anti-glioma therapy. Acta Biomater. 2016 Jul 1;38:69-81. doi: 10.1016/j.actbio.2016.04.026. Epub 2016 Apr 19. PMID: 27109765. 2: Baum RP, Kluge AW, Kulkarni H, Schorr-Neufing U, Niepsch K, Bitterlich N, van Echteld CJ. [(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study. Theranostics. 2016 Feb 13;6(4):501-10. doi: 10.7150/thno.13702. PMID: 26941843; PMCID: PMC4775860. 3: Schottelius M, Wester HJ, Reubi JC, Senekowitsch-Schmidtke R, Schwaiger M. Improvement of pharmacokinetics of radioiodinated Tyr(3)-octreotide by conjugation with carbohydrates. Bioconjug Chem. 2002 Sep-Oct;13(5):1021-30. doi: 10.1021/bc0200069. PMID: 12236784. 4: Yim CB, Dijkgraaf I, Merkx R, Versluis C, Eek A, Mulder GE, Rijkers DT, Boerman OC, Liskamp RM. Synthesis of DOTA-conjugated multimeric [Tyr3]octreotide peptides via a combination of Cu(I)-catalyzed "click" cycloaddition and thio acid/sulfonyl azide "sulfo-click" amidation and their in vivo evaluation. J Med Chem. 2010 May 27;53(10):3944-53. doi: 10.1021/jm100246m. PMID: 20411957. 5: Schirmer WJ, O'Dorisio TM, Schirmer TP, Mojzisik CM, Hinkle GH, Martin EW. Intraoperative localization of neuroendocrine tumors with 125I-TYR(3)-octreotide and a hand-held gamma-detecting probe. Surgery. 1993 Oct;114(4):745-51; discussion 751-2. PMID: 8211689. 6: Nocaudie-Calzada M, Huglo D, Deveaux M, Carnaille B, Proye C, Marchandise X. Iodine-123-Tyr-3-octreotide uptake in pancreatic endocrine tumors and in carcinoids in relation to hormonal inhibition by octreotide. J Nucl Med. 1994 Jan;35(1):57-62. PMID: 8271061. 7: Virgolini I, Angelberger P, Li S, Yang Q, Kurtaran A, Raderer M, Neuhold N, Kaserer K, Leimer M, Peck-Radosavljevic M, Scheithauer W, Niederle B, Eichler HG, Valent P. In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-octreotide (OCT), 123I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCT. Eur J Nucl Med. 1996 Oct;23(10):1388-99. doi: 10.1007/BF01367597. PMID: 8781146. 8: Leitha T, Meghdadi S, Studnicka M, Wolzt M, Marosi C, Angelberger P, Neumann M, Schlick W, Kletter K, Dudczak R. The role of iodine-123-Tyr-3-octreotide scintigraphy in the staging of small-cell lung cancer. J Nucl Med. 1993 Sep;34(9):1397-402. PMID: 8394882. 9: Maresca KP, Marquis JC, Hillier SM, Lu G, Femia FJ, Zimmerman CN, Eckelman WC, Joyal JL, Babich JW. Novel polar single amino acid chelates for technetium-99m tricarbonyl-based radiopharmaceuticals with enhanced renal clearance: application to octreotide. Bioconjug Chem. 2010 Jun 16;21(6):1032-42. doi: 10.1021/bc900517x. PMID: 20402463. 10: Wester HJ, Schottelius M, Scheidhauer K, Reubi JC, Wolf I, Schwaiger M. Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydration on the pharmacokinetics. Eur J Nucl Med Mol Imaging. 2002 Jan;29(1):28-38. doi: 10.1007/s00259-001-0669-1. Epub 2001 Nov 1. PMID: 11807604. 11: de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, Bugaj JE, Erion J, Schmidt M, Srinivasan A, Krenning EP. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer. 2001 Jun 1;92(5):628-33. doi: 10.1002/1097-0215(20010601)92:5<628::aid- ijc1244>3.0.co;2-l. PMID: 11340564. 12: Bomanji J, Mather S, Moyes J, Ellison D, Grossman A, Britton KE, Besser GM. A scintigraphic comparison of iodine-123-metaiodobenzylguanidine and an iodine- labeled somatostatin analog (Tyr-3-octreotide) in metastatic carcinoid tumors. J Nucl Med. 1992 Jun;33(6):1121-4. PMID: 1597726. 13: Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, Lameris JS, Reubi JC, Lamberts SW. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet. 1989 Feb 4;1(8632):242-4. doi: 10.1016/s0140-6736(89)91258-0. PMID: 2563413. 14: Bakker WH, Krenning EP, Breeman WA, Koper JW, Kooij PP, Reubi JC, Klijn JG, Visser TJ, Docter R, Lamberts SW. Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animals. J Nucl Med. 1990 Sep;31(9):1501-9. PMID: 1975618. 15: Capello A, Krenning EP, Breeman WA, Bernard BF, Konijnenberg MW, de Jong M. Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitro. Cancer Biother Radiopharm. 2003 Oct;18(5):761-8. doi: 10.1089/108497803770418300. PMID: 14629824. 16: van Wamel A, Bouakaz A, Bernard B, ten Cate F, de Jong N. Radionuclide tumour therapy with ultrasound contrast microbubbles. Ultrasonics. 2004 Apr;42(1-9):903-6. doi: 10.1016/j.ultras.2003.11.013. PMID: 15047404. 17: Robben JH, Visser-Wisselaar HA, Rutteman GR, van Rijk PP, van Dongen AJ, Voorhout G, van den Ingh TS, Hofland LJ, Lamberts SW. In vitro and in vivo detection of functional somatostatin receptors in canine insulinomas. J Nucl Med. 1997 Jul;38(7):1036-42. PMID: 9225787. 18: Surujpaul PP, Gutiérrez-Wing C, Ocampo-García B, Ramírez Fde M, Arteaga de Murphy C, Pedraza-López M, Camacho-López MA, Ferro-Flores G. Gold nanoparticles conjugated to [Tyr3]octreotide peptide. Biophys Chem. 2008 Dec;138(3):83-90. doi: 10.1016/j.bpc.2008.09.005. Epub 2008 Sep 14. PMID: 18819743. 19: Ur E, Bomanji J, Mather SJ, Britton KE, Wass JA, Grossman AB, Besser GM. Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide. Clin Endocrinol (Oxf). 1993 May;38(5):501-6. doi: 10.1111/j.1365-2265.1993.tb00346.x. PMID: 8101146. 20: Decristoforo C, Mather SJ. Technetium-99m somatostatin analogues: effect of labelling methods and peptide sequence. Eur J Nucl Med. 1999 Aug;26(8):869-76. doi: 10.1007/s002590050461. PMID: 10436200.